BIOTECH · FDA approves Egetis' Emcitate for rare MCT8 disorder
Emcitate is now the only approved treatment for a rare genetic disease that Endpoints reports used to cut life expectancy to about 35 years.
@thedailyfathom.bsky.socialExplore
@thedailyfathom.bsky.social